Clinical Trial Results: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in hematologic and myeloproliferative malignancies; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Marrow Disease
• Leukemia
• Myelodysplastic Myeloproliferative Neoplasm
• Myelodysplastic Syndrome
• Myelofibrosis
• Myeloproliferative Disorders
• Preleukemia

Drugs mentioned

• CPI-0610 (CPI-0610)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Constellation Pharmaceuticals | Conditions: Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-06-04